1. Home
  2. Knowledge Base
  3. References
  4. An agonistic antibody to EPHA2 exhibits antitumor effects on human melanoma cells

An agonistic antibody to EPHA2 exhibits antitumor effects on human melanoma cells

Sakamoto A, Kato K, Hasegawa T, Ikeda S (2018) An agonistic antibody to EPHA2 exhibits antitumor effects on human melanoma cells. Anticancer Res 38:3273-3282. doi: 10.21873/anticanres.12592

Objective: Investigate the therapeutic potential of antibody to EPHA2 against melanoma in vitro.

Summary: Observations indicate a promising role for EPHA2 as a target in antibody treatments for melanoma, and demonstrate the potential therapeutic effects of an agonistic antibody to EPHA2.

Usage: A375 cells were plated into a flat-bottom, 96-well plate (2,000 cells per well) and incubated for 4 days at 37˚C. Cell suspension included different concentrations of Mab-ZAP, along with either anti-EPHA2 mAb (SHM16, SHM17, or SHM20 at 2 μg/ml final concentration), or a control IgG1 mAb (2 μg/ml final concentration).

Related Products: Mab-ZAP (Cat. #IT-04)

Browse Articles

Need Support?

Can't find what you're looking for? Contact us, we're here to help!